By the same reasoning, an IgA mAb could also be suitable as a prophylactic immunotherapy, especially for individuals who have already experienced a primary infection and whose window of potential re-exposure is known in advance (e.g., travelers, military personnel). This evidence concerns the gene CD79A and infection.